C3PO
Condition: COVID-19
Eligibility
Key Inclusion Criteria:
- Emergency Department patient who:
- Has one or more symptoms of COVID-19 illness and laboratory
- Confirmed SARS-CoV-2 infection
- Has at least one risk factor for severe COVID-19 illness
- Is stable for outpatient management without supplemental oxygen
Key Exclusion Criteria:
- Less than 18 years old
- Prior adverse reaction(s) from blood product transfusion
- Receipt of any blood product within the past 120 days
Study Name:
Clinical Trial of COVID-19 Convalescent Plasma in Outpatients: A Multicenter, Two-Arm, Randomized, Single-Blind Clinical Trial to Determine if Receiving One Dose of Convalescent Plasma (CP) for Mild COVID-19 Illness Prevents Illness Progression (IRB no. 00000891)
Summary
The purpose of this study is to determine whether giving convalescent plasma (CP) to individuals with mild COVID-19 illness can prevent progression to severe illness that requires hospital admission. Convalescent plasma (CP) is made from the blood of individuals who have recovered from COVID-19; it contains proteins that may fight COVID-19 infection (antibodies). The antibodies may also protect participants from becoming infected with the virus again. The use of CP for COVID-19 illness is investigational. Participants will be randomly assigned to receive either CP or placebo (inactive substance).
Principal Investigator
Contact
Pulmonary Research Team
310-423-8474
GroupLungResearch@cshs.org